{"success":true,"data":{"pressRelease":{"id":"170344","rtpr_id":"nGNX1dfcJW-20261015","ticker":"CYDY","exchange":"OTC","all_tickers":["CYDY"],"title":"CytoDyn to Host Investor Webcast","author":"Globe Newswire","published_at":"2026-10-15T12:30:01.117Z","article_body":"VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:\nCYDY) (\"CytoDyn\" or the \"Company\"), a clinical-stage oncology company\nadvancing leronlimab, a first-in-class humanized monoclonal antibody targeting\nthe CCR5 receptor with therapeutic potential across multiple solid-tumor\noncology indications, including colorectal cancer (“mCRC”) and metastatic\ntriple-negative breast cancer (“mTNBC”), today announced it will host an\ninvestor webcast on October 19, 2026, at 1 p.m. PT, to provide a corporate and\nclinical update.\n\nThe investor webcast will highlight CytoDyn’s latest scientific, clinical,\noperational, and financial progress, as well as calendar 2026 priorities and\nupcoming milestones. Dr. Jacob P. Lalezari, CEO of CytoDyn, will be joined by\nRobert E. Hoffman, CFO of CytoDyn, and Pashtoon M. Kasi, M.D., M.S., Medical\nDirector of GI Oncology, City of Hope Orange County, Irvine, California. Reny\nAniline, Senior Director of BioPharma Business Development of Natera, Inc.,\nwill also participate in the webcast to discuss the recently announced\nstrategic collaboration between Natera and CytoDyn, and to provide further\ncontext on the early ctDNA observations in CytoDyn’s CLOVER study.\n\nDate: Monday, October 19, 2026\n\nTime: 1 p.m. PT\n\nRegistration and Access Link\n(https://www.globenewswire.com/Tracker?data=hQgQXowLsELrtFquGdmxIlBbv1PwkisJ3OtZMr0vCZgjQpLPWSSGJiq6l1VZsQc4h3XmgJBC74Cyta5xjg7xXdMp6orMcLbluywga0D3tARaZCdivzm6103812JD3JNNJz0G8t6uYzoGsGo_DP_MQ55CDWk0D-dl9Qi3lt_dyP06p0YocaPSVe-j7sqdDimS)\n\nThis is a livestream presentation. Attendees are advised to log in ahead of\nthe start time. The Company will host a live Q&A session during the webcast;\nquestions may be submitted in advance to ir@cytodyn.com.\n\nFollowing the conclusion of the webcast, a replay will be available for\napproximately 30 days in the investor relations section\n(https://www.globenewswire.com/Tracker?data=dFLJssccrXO-PMeY0nKxwHGHfNMtTt4Eij6cmVvsjnUAMqypwATblV1_kcaohxFQJnjCjI30ro8LcWo9lgFJPQM-oq9xhlqvqVNR6fCaARCxfKc0wp2lA1_LYmDDS679)\nof the Company’s website.\n\nAbout CytoDyn\n\nCytoDyn is a clinical-stage oncology company dedicated to advancing\nleronlimab, a first-in-class humanized monoclonal antibody that targets the\nCCR5 receptor, a key regulator of immune function implicated in cancer,\ninfectious diseases, and autoimmune disorders. Guided by a mission to improve\npatients’ quality of life through therapeutic innovation, CytoDyn is\ncommitted to integrity, responsibility, and service as it works to bring\ntransformative treatments to patients worldwide.\n\nFor more information, please visit www.cytodyn.com and follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=Q3-wVlaeC7tviUnocrK-Q4W4QT5GrghmB1MfzO3eYIkwRJ5GLalsr6LwJ7UqBiUcglD4kVD3XzGnI_VC0ZzXlnwLRFufFxQpniRXCmFJ4B0brLudasd8ssRjch7Hh-2tf-amA-T1LCjpCysgnr49WrFnUDcOSIdQKyh0OyDgzUFwWDU9VkknHmtxtIpujDif6BH3AbnZUrFlmfCrg1-XhDmWc1dwRJg3buAJXmxlSaCXihNGTxCeXjNUV4hEz32vPtWRS0A1rZ-MCqvOPKRA4gGG4CszVOfsIbHd9vJsHd9ehFCFTl1lVrBLjqpJ8e3FpKIll_ShPHLT0llUQhChBZVoN0zeZpR9aNimBBx46NItC8lpgQQQ_NK5cMOZnx_y9HMOB0NwINR2ANbK66MM1maewPHOpM2UwirqbpSr6FLWPZKagPqtKEEhU050R_a1).\n\nNote Regarding Forward-Looking Statements\n\nThis news release may contain forward-looking statements relating to, among\nother things, the mechanism of action of leronlimab, clinical trial results,\nproduct development, market position, future operating and financial\nperformance, and business strategy. The reader is cautioned not to rely on\nthese statements, which are based on current expectations of future events.\nFor important information about these statements and our Company, including\nthe risks, uncertainties and other factors that could cause actual results to\nvary materially from the assumptions, expectations and projections expressed\nin any forward-looking statements, the reader should review our Annual Report\non Form 10-K for the fiscal year ended May 31, 2026, including the section\ncaptioned “Forward-Looking Statements” and in Item 1A, as well as\nsubsequent reports filed with the Securities and Exchange Commission. CytoDyn\nInc. does not undertake to update any forward-looking statement as a result of\nnew information or future events or developments except as required by\napplicable law.\n\nCorporate Contact\nCytoDyn Inc.\nir@cytodyn.com\n\nMedia Contacts\nDavid Schull or Ignacio Guerrero-Ros, Ph.D.\nRusso Partners, LLC\nCytoDyn@russopartnersllc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1dfcJW-20261015","title":"CytoDyn to Host Investor Webcast","author":"Globe Newswire","ticker":"CYDY","created":"2026-10-15T12:30:01.117Z","tickers":["CYDY"],"exchange":"OTC","article_body":"VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:\nCYDY) (\"CytoDyn\" or the \"Company\"), a clinical-stage oncology company\nadvancing leronlimab, a first-in-class humanized monoclonal antibody targeting\nthe CCR5 receptor with therapeutic potential across multiple solid-tumor\noncology indications, including colorectal cancer (“mCRC”) and metastatic\ntriple-negative breast cancer (“mTNBC”), today announced it will host an\ninvestor webcast on October 19, 2026, at 1 p.m. PT, to provide a corporate and\nclinical update.\n\nThe investor webcast will highlight CytoDyn’s latest scientific, clinical,\noperational, and financial progress, as well as calendar 2026 priorities and\nupcoming milestones. Dr. Jacob P. Lalezari, CEO of CytoDyn, will be joined by\nRobert E. Hoffman, CFO of CytoDyn, and Pashtoon M. Kasi, M.D., M.S., Medical\nDirector of GI Oncology, City of Hope Orange County, Irvine, California. Reny\nAniline, Senior Director of BioPharma Business Development of Natera, Inc.,\nwill also participate in the webcast to discuss the recently announced\nstrategic collaboration between Natera and CytoDyn, and to provide further\ncontext on the early ctDNA observations in CytoDyn’s CLOVER study.\n\nDate: Monday, October 19, 2026\n\nTime: 1 p.m. PT\n\nRegistration and Access Link\n(https://www.globenewswire.com/Tracker?data=hQgQXowLsELrtFquGdmxIlBbv1PwkisJ3OtZMr0vCZgjQpLPWSSGJiq6l1VZsQc4h3XmgJBC74Cyta5xjg7xXdMp6orMcLbluywga0D3tARaZCdivzm6103812JD3JNNJz0G8t6uYzoGsGo_DP_MQ55CDWk0D-dl9Qi3lt_dyP06p0YocaPSVe-j7sqdDimS)\n\nThis is a livestream presentation. Attendees are advised to log in ahead of\nthe start time. The Company will host a live Q&A session during the webcast;\nquestions may be submitted in advance to ir@cytodyn.com.\n\nFollowing the conclusion of the webcast, a replay will be available for\napproximately 30 days in the investor relations section\n(https://www.globenewswire.com/Tracker?data=dFLJssccrXO-PMeY0nKxwHGHfNMtTt4Eij6cmVvsjnUAMqypwATblV1_kcaohxFQJnjCjI30ro8LcWo9lgFJPQM-oq9xhlqvqVNR6fCaARCxfKc0wp2lA1_LYmDDS679)\nof the Company’s website.\n\nAbout CytoDyn\n\nCytoDyn is a clinical-stage oncology company dedicated to advancing\nleronlimab, a first-in-class humanized monoclonal antibody that targets the\nCCR5 receptor, a key regulator of immune function implicated in cancer,\ninfectious diseases, and autoimmune disorders. Guided by a mission to improve\npatients’ quality of life through therapeutic innovation, CytoDyn is\ncommitted to integrity, responsibility, and service as it works to bring\ntransformative treatments to patients worldwide.\n\nFor more information, please visit www.cytodyn.com and follow us\non LinkedIn\n(https://www.globenewswire.com/Tracker?data=Q3-wVlaeC7tviUnocrK-Q4W4QT5GrghmB1MfzO3eYIkwRJ5GLalsr6LwJ7UqBiUcglD4kVD3XzGnI_VC0ZzXlnwLRFufFxQpniRXCmFJ4B0brLudasd8ssRjch7Hh-2tf-amA-T1LCjpCysgnr49WrFnUDcOSIdQKyh0OyDgzUFwWDU9VkknHmtxtIpujDif6BH3AbnZUrFlmfCrg1-XhDmWc1dwRJg3buAJXmxlSaCXihNGTxCeXjNUV4hEz32vPtWRS0A1rZ-MCqvOPKRA4gGG4CszVOfsIbHd9vJsHd9ehFCFTl1lVrBLjqpJ8e3FpKIll_ShPHLT0llUQhChBZVoN0zeZpR9aNimBBx46NItC8lpgQQQ_NK5cMOZnx_y9HMOB0NwINR2ANbK66MM1maewPHOpM2UwirqbpSr6FLWPZKagPqtKEEhU050R_a1).\n\nNote Regarding Forward-Looking Statements\n\nThis news release may contain forward-looking statements relating to, among\nother things, the mechanism of action of leronlimab, clinical trial results,\nproduct development, market position, future operating and financial\nperformance, and business strategy. The reader is cautioned not to rely on\nthese statements, which are based on current expectations of future events.\nFor important information about these statements and our Company, including\nthe risks, uncertainties and other factors that could cause actual results to\nvary materially from the assumptions, expectations and projections expressed\nin any forward-looking statements, the reader should review our Annual Report\non Form 10-K for the fiscal year ended May 31, 2026, including the section\ncaptioned “Forward-Looking Statements” and in Item 1A, as well as\nsubsequent reports filed with the Securities and Exchange Commission. CytoDyn\nInc. does not undertake to update any forward-looking statement as a result of\nnew information or future events or developments except as required by\napplicable law.\n\nCorporate Contact\nCytoDyn Inc.\nir@cytodyn.com\n\nMedia Contacts\nDavid Schull or Ignacio Guerrero-Ros, Ph.D.\nRusso Partners, LLC\nCytoDyn@russopartnersllc.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T12:30:01.612246721Z","server_sent_at_ms":1792067401612},"received_at":"2026-10-15T12:30:01.663Z","source_url":null},"analysis":{"id":"158534","press_release_id":"170344","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"CytoDyn announced an investor webcast on October 19, 2026, at 1 p.m. PT to provide a corporate and clinical update on leronlimab, its CCR5-targeting monoclonal antibody in oncology.\n\nThe webcast will feature CEO Dr. Jacob Lalezari and CFO Robert Hoffman, plus representatives from City of Hope and Natera discussing their strategic collaboration and early ctDNA observations from the CLOVER study.\n\nThis is a scheduling notice with no new clinical or financial data; the webcast may preview upcoming 2026 milestones.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Webcast scheduling notice — watch October 19 for possible CLOVER ctDNA and collaboration updates."},"keyFigures":{},"namedEntities":{"people":[{"name":"Jacob P. Lalezari","role":"CEO"},{"name":"Robert E. Hoffman","role":"CFO"},{"name":"Pashtoon M. Kasi","role":"Medical Director of GI Oncology, City of Hope Orange County"},{"name":"Reny Aniline","role":"Senior Director of BioPharma Business Development, Natera"}],"products":["leronlimab"],"companies":[{"name":"CytoDyn Inc.","ticker":"CYDY","relationship":"filer"},{"name":"Natera, Inc.","relationship":"partner"},{"name":"City of Hope Orange County","relationship":"clinical collaborator"},{"name":"Russo Partners, LLC","relationship":"media relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Announcement of an upcoming investor webcast with no new results, guidance, or figures. Event notice only."},"tickerRelevance":{"others":[],"primary":"CYDY"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"webcast-announcement","issuerAuthored":true,"retailFavoriteBoost":"CYDY has retail following"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"CytoDyn announced an investor webcast on October 19, 2026, at 1 p.m. PT to provide a corporate and clinical update on leronlimab, its CCR5-targeting monoclonal antibody in oncology.\n\nThe webcast will feature CEO Dr. Jacob Lalezari and CFO Robert Hoffman, plus representatives from City of Hope and Natera discussing their strategic collaboration and early ctDNA observations from the CLOVER study.\n\nThis is a scheduling notice with no new clinical or financial data; the webcast may preview upcoming 2026 milestones.","key_figures":{},"named_entities":{"people":[{"name":"Jacob P. Lalezari","role":"CEO"},{"name":"Robert E. Hoffman","role":"CFO"},{"name":"Pashtoon M. Kasi","role":"Medical Director of GI Oncology, City of Hope Orange County"},{"name":"Reny Aniline","role":"Senior Director of BioPharma Business Development, Natera"}],"products":["leronlimab"],"companies":[{"name":"CytoDyn Inc.","ticker":"CYDY","relationship":"filer"},{"name":"Natera, Inc.","relationship":"partner"},{"name":"City of Hope Orange County","relationship":"clinical collaborator"},{"name":"Russo Partners, LLC","relationship":"media relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T12:30:19.347Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"webcast-announcement","issuerAuthored":true,"retailFavoriteBoost":"CYDY has retail following"}},"durationMs":4413,"modelName":"glm-5.3-flashx"}}